Literature DB >> 11696428

Restricted killer cell immunoglobulin-like receptor repertoire without T-cell receptor gamma rearrangement supports a true natural killer-cell lineage in a subset of sinonasal lymphomas.

C W Lin1, W H Lee, C L Chang, J Y Yang, S M Hsu.   

Abstract

The cellular lineage of sinonasal T/NK (natural killer) cell lymphoma remains controversial. Lineage assignment is difficult because T cells and NK cells have a similar morphology and surface markers. Consequently, the assignment must depend heavily on the status of T-cell receptor (TCR) rearrangement. A monoclonal TCR rearrangement supports a T lineage; however, a corresponding monoclonality test for NK cells has not yet been established. Each NK cell bears a distinct set of killer cell immunoglobulin (Ig)-like receptors (KIRs) that are randomly distributed over three groups. In principle, restriction of the KIR repertoire signifies a monoclonal or possibly oligoclonal NK-cell proliferation, just as Ig light-chain restriction usually indicates a monoclonal B-cell neoplasm. Using a novel group-specific reverse transcriptase-polymerase chain reaction, we found a restricted KIR repertoire in most sinonasal lymphomas (9 of 10), but only rarely in T-cell lymphomas (2 of 10) or reactive conditions involving T/NK cells (1 of 10). KIR+ sinonasal lymphomas usually lacked a monoclonal TCR-gamma rearrangement pattern, expressed another NK cell receptor, NKG2a, and were usually CD56-positve, cyclin-dependent kinase-6 (CDK6)-positive, CD44-negative, a phenotype already reported to indicate a true NK cell lineage. We conclude that, although sinonasal lymphomas have heterogeneous genotypes and phenotypes, a restricted KIR repertoire without TCR-gamma rearrangement provides preliminary support for the monoclonality hypothesis and can be used for defining a true NK-cell lineage in a subset of sinonasal lymphomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696428      PMCID: PMC1867044          DOI: 10.1016/s0002-9440(10)63014-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.

Authors:  M C Mingari; C Vitale; C Cantoni; R Bellomo; M Ponte; F Schiavetti; S Bertone; A Moretta; L Moretta
Journal:  Eur J Immunol       Date:  1997-06       Impact factor: 5.532

2.  Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations.

Authors:  M C Mingari; F Schiavetti; M Ponte; C Vitale; E Maggi; S Romagnani; J Demarest; G Pantaleo; A S Fauci; L Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  Nucleotide and amino acid sequence alignment for human killer cell inhibitory receptors (KIR), 1998.

Authors:  U Steffens; Y Vyas; B Dupont; A Selvakumar
Journal:  Tissue Antigens       Date:  1998-04

4.  Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis.

Authors:  S Signoretti; M Murphy; M G Cangi; P Puddu; M E Kadin; M Loda
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

5.  Tonsillar lymphocyte subsets in recurrent acute tonsillitis and tonsillar hypertrophy.

Authors:  M A López-González; B Sánchez; F Mata; F Delgado
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1998-02       Impact factor: 1.675

Review 6.  Development and tolerance of natural killer cells.

Authors:  D H Raulet
Journal:  Curr Opin Immunol       Date:  1999-04       Impact factor: 7.486

7.  Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage.

Authors:  A K Chiang; A C Chan; G Srivastava; F C Ho
Journal:  Int J Cancer       Date:  1997-11-04       Impact factor: 7.396

8.  Human diversity in killer cell inhibitory receptor genes.

Authors:  M Uhrberg; N M Valiante; B P Shum; H G Shilling; K Lienert-Weidenbach; B Corliss; D Tyan; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

9.  Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.

Authors:  N M Valiante; M Uhrberg; H G Shilling; K Lienert-Weidenbach; K L Arnett; A D'Andrea; J H Phillips; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

10.  Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.

Authors:  M Chilosi; C Doglioni; Z Yan; M Lestani; F Menestrina; C Sorio; A Benedetti; F Vinante; G Pizzolo; G Inghirami
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

View more
  4 in total

1.  Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma.

Authors:  Can Küçük; Xiaozhou Hu; Qiang Gong; Bei Jiang; Adam Cornish; Philippe Gaulard; Timothy McKeithan; Wing C Chan
Journal:  Am J Pathol       Date:  2016-04-07       Impact factor: 4.307

Review 2.  Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets.

Authors:  Christian Schmitt; Nouhoum Sako; Martine Bagot; Yenlin Huang; Philippe Gaulard; Armand Bensussan
Journal:  J Biomed Biotechnol       Date:  2011-04-20

3.  Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand.

Authors:  Tawatchai Pongpruttipan; Tanawan Kummalue; Anan Bedavanija; Archrob Khuhapinant; Koichi Ohshima; Fumiko Arakawa; Daisuke Niino; Sanya Sukpanichnant
Journal:  Diagn Pathol       Date:  2011-08-25       Impact factor: 2.644

Review 4.  The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.

Authors:  Hyunsung Kim; Young Hyeh Ko
Journal:  Life (Basel)       Date:  2022-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.